Semaglutide, the active ingredient in Ozempic, has shown promising results in weight loss and blood sugar management. But did ...

Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy, have ...

2024年9月，诺和诺德成功完成了STRIDE临床3b期试验。这是一项为期52周的试验，比较了1.0 ...

Novo Nordisk, the maker of Ozempic, reported that compounded versions of semaglutide, the main ingredient in Ozempic and ...

Recent studies have found that Ozempic could lead to more muscle mass loss than traditional weight loss methods.

Ozempic (semaglutide) is a well-known prescription drug that’s used to treat blood sugar of people with type 2 diabetes, has ...

The ‘Ozempic drug,’ semaglutide, has been found to reduce moderately severe pain caused by knee osteoarthritis and improve ...

智通财经APP获悉，诺和诺德(NVO.US)首席财务官Karsten Munk Knudsen周三表示，该公司了解到，有100人因服用其畅销减肥药和糖尿病药的复方仿制药而住院，10人死亡。

不过，Novo Nordisk开发副总裁Martin Holst Lange向分析师表示，他“有信心”更大规模的试验会证明CagriSema能帮助用户减重多达25%。Lange指出，公司基于先前试验的数据得出了这一预测。 Novo Nordisk表示，根据此前的试验，这款新药的安全性和耐受性预计与当前市面上的GLP-1药物相似。

在全球肥胖问题愈演愈烈的背景下，诺和诺德（Novo ...

诺和诺德 (NVO.US)首席财务官Karsten Munk Knudsen周三表示，该公司了解到，有100人因服用其畅销减肥药和糖尿病药的复方仿制药而住院，10人死亡。 上个月，诺和诺德请求美国食品药品监督管理局 (FDA)禁止复方制剂厂商生产Wegovy和Ozempic的仿制品，称这两种药物过于复杂，制药商无法安全生产。

Ozempic (semaglutide) may impact kidney health in certain people, especially those with diabetes. Learn more about what the ...